Indrayani Biotech Sets 34th AGM, Proposes ₹25 Crore RPT Caps

Indrayani Biotech Limited has scheduled its 34th Annual General Meeting for November 30, 2026, while seeking shareholder approval for related-party transactions of up to ₹25 crore each with six subsidiaries. The board decisions set the company’s AGM timetable, voting process and proposed governance appointments for FY 2026-27.

When will Indrayani Biotech hold its 34th AGM?

Indrayani Biotech will hold its 34th Annual General Meeting on Monday, November 30, 2026, at 4:00 PM IST through video conferencing and other audio-visual means. The date was approved at the company’s Board of Directors meeting held on November 6, 2026.

The AGM notice and annual report are expected to be dispatched to shareholders by November 7, 2026. The board has also authorised their dispatch, completing a key procedural step before the general meeting. The meeting follows an extension of time granted to the company for holding its AGM for FY 2025-26, as disclosed in September 2026.

Indrayani Biotech had informed BSE Limited on November 3 that its board would meet to consider and approve the draft notice for the 34th AGM. The November 6 outcome confirms the proposed agenda and the arrangements through which shareholders can participate and vote remotely.

What related-party transaction approval is Indrayani Biotech seeking?

Indrayani Biotech is seeking shareholder approval for material related-party transactions of up to ₹25 crore each with six subsidiaries. The board’s approval remains subject to shareholder approval at the AGM.

The subsidiaries named in the proposal are Dindigul Farm Product Limited, Matrix Boilers Private Limited, HSL Agri Solutions Limited, HSLPrime Properties Private Limited, IBL Investments Limited and IBL Healthcare Limited. The disclosed ₹25 crore ceiling applies to each transaction with these entities, rather than being stated as one combined limit for all six subsidiaries.

Related-party transactions require particular scrutiny because they involve entities connected to the listed company. The AGM proposal gives shareholders the opportunity to consider the stated transaction limits before the arrangements can proceed under the board’s approval framework. The available disclosure does not provide transaction-wise values, terms, or a combined value of the proposed dealings.

How will Indrayani Biotech shareholders vote at the AGM?

Indrayani Biotech has fixed November 23, 2026, as the cut-off date for determining shareholders eligible to vote on AGM resolutions. Shareholders holding securities on that date will be entitled to use the voting process outlined in the AGM notice.

Remote e-voting will open at 9:00 AM on November 27, 2026, and close at 5:00 PM on November 29, 2026. MUFG Intime India Private Limited will provide the remote e-voting facility. KRA & Associates has been appointed as scrutinizer for the voting process.

The company has set its book closure period from November 24 through November 30, 2026, with both dates included. The results of remote e-voting are expected to be declared by December 2, 2026. These dates provide the operational sequence for shareholders ahead of the virtual meeting.

What governance actions did Indrayani Biotech’s board approve?

Indrayani Biotech appointed M/s Vaithianathan & Associates as Internal Auditor for FY 2026-27. The board also considered the appointment of Ms. Nattery Srinivasan Poornima as Secretarial Auditor for a five-year term, subject to the required shareholder process at the AGM.

The board approved the company’s Policy for Determination of Materiality of Events or Information. Such a policy sets the basis for deciding which events or information require disclosure by a listed company, in line with its disclosure obligations.

These governance actions form part of the AGM agenda alongside approval of the FY26 directors’ report and notice. The company’s prior annual-report disclosures note compliance with Secretarial Standards on board meetings and general meetings, though the current board outcome concerns the specific appointments and processes for the forthcoming AGM.

Why do the AGM decisions matter to investors?

The AGM is the forum where eligible shareholders can vote on resolutions placed before them, including the proposed related-party transaction limits and the secretarial auditor appointment. The disclosed timetable gives investors the dates needed to check eligibility, receive the annual report and cast their vote.

The ₹25 crore cap is the most material financial figure in the board outcome because it sets an upper limit for each proposed subsidiary-related transaction. However, the disclosure does not state the expected value of individual transactions, their commercial purpose, or their effect on Indrayani Biotech’s revenue, margins, cash flows or consolidated financial position.

No share-price movement, trading volume, earnings update or revised financial outlook was included in the information provided. Investors therefore have a governance and approval-related disclosure rather than a financial-performance announcement. The AGM notice and annual report, once dispatched, will be important documents for reviewing the resolutions and accompanying explanations.

Conclusion

Indrayani Biotech has formalised the schedule for its 34th AGM and placed proposed related-party transaction limits of ₹25 crore each with six subsidiaries before shareholders. The board has also set the e-voting framework, appointed an internal auditor for FY 2026-27 and advanced the process for a five-year secretarial auditor appointment.

Shareholders can watch for the expected dispatch of the AGM notice and annual report by November 7, 2026, the November 23 voting cut-off date, and the voting results expected by December 2, 2026. The AGM vote will determine whether the related-party transaction proposal and other shareholder resolutions receive approval.